12:00 AM
 | 
Oct 26, 2009
 |  BC Week In Review  |  Company News  |  Deals

Tarsa Therapeutics, Unigene deal

Newco Tarsa received an exclusive, worldwide license, excluding China, to develop and commercialize Unigene's oral calcitonin. The osteoclast inhibitor is in Phase III testing for osteoporosis, with data...

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >